Icatibant Teva

Icatibant acetate, the active ingredient in Icatibant Teva, is a bradykinin B2 receptor antagonist presented as a 30 mg/0.3 mL prefilled syringe for subcutaneous use. It treats acute attacks of hereditary angioedema type I and type II in patients with a confirmed diagnosis and is indicated for rapid symptom control during life‑threatening swelling episodes.

GNH USA supplies Icatibant Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, clinics and other healthcare facilities worldwide, ensuring quality, regulatory compliance and reliable access to this specialty therapy for qualified providers.

Icatibant Teva is used to manage hereditary angioedema, a bradykinin‑mediated swelling disorder. Hereditary angioedema type I: reduces severity and shortens duration of acute swelling attacks. Hereditary angioedema type II: provides rapid relief of symptoms during acute episodes. Hereditary angioedema attacks (any type): offers prompt control of edema and associated pain.

Icatibant Teva may cause a range of adverse reactions following subcutaneous administration.

Common Side Effects: - Injection site pain: mild to moderate discomfort at the injection site. - Redness: localized erythema around the injection area. - Swelling: transient edema at the site of administration. - Nausea: occasional feeling of queasiness.

Serious or Rare Side Effects: - Hypersensitivity reaction: rash, urticaria, or anaphylaxis requiring immediate medical attention. - Severe abdominal pain: persistent intense pain that may indicate a serious complication. - Thrombocytopenia: rare drop in platelet count observed in post‑marketing reports.

Before using Icatibant Teva, consider the following precautions. Pregnancy: safety not established; use only if potential benefit justifies risk. Breastfeeding: unknown; consider risk versus benefit. Renal impairment: no dosage adjustment required, but monitor closely. Concomitant ACE inhibitors: may increase bradykinin levels; observe for enhanced swelling. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Icatibant Teva can interact with other medicines; review the following categories. Major Interactions (Avoid): - ACE inhibitors: additive bradykinin effect may worsen angioedema. - Angiotensin receptor blockers: similar risk of increased bradykinin. Moderate Interactions (Monitor Closely): - Estrogen‑containing contraceptives: may increase frequency of HAE attacks; monitor. - Other B2 receptor antagonists: potential additive effect; observe response. - Immunosuppressants: no direct interaction but monitor infection risk.